Pharmaceutical

Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019

Tuesday, November 12, 2019 - 7:00am

POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).
  • In the poster presentation, PXL065 was observed to have a favorable safety, tolerability and PK profile in the Phase 1a trial.
  • Based on preclinical and clinical results, I am excited about the potential for an improved therapeutic profile for PXL065 compared to pioglitazone.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.

Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS

Tuesday, November 12, 2019 - 6:00am

Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement.

Key Points: 
  • Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement.
  • In conjunction with todays alliance, MEDIPAL has decided to increase its shareholdings in the Promethera Group.
  • Promethera completed the recruitment of 24 patients in its Phase 2a study in Acute-on-chronic liver failure (ACLF) in July 2019.
  • As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

Tuesday, November 12, 2019 - 2:50am

NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines.

Key Points: 
  • NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines.
  • View the full release here: https://www.businesswire.com/news/home/20191111005716/en/
    Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial.
  • NEC and VAXIMM will co-develop personalized cancer vaccines using NECs cutting-edge artificial intelligence (AI) technology, which is utilized in its Neoantigen Prediction System, and VAXIMMs proprietary T-cell immunotherapy technology.
  • NECs neoantigen prediction utilizes its proprietary AI which is combined with NEC OncoImmunity ASs bioinformatics pipelines making it the leading neoantigen prediction system in the field.

Organigram Provides Corporate Update

Monday, November 11, 2019 - 11:30pm

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, provided a corporate update today and announced details for its fiscal fourth quarter ended August 31, 2019 (Q4 2019) and full year 2019 conference call.

Key Points: 
  • Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, provided a corporate update today and announced details for its fiscal fourth quarter ended August 31, 2019 (Q4 2019) and full year 2019 conference call.
  • This is particularly relevant for LPs with strong distribution like Organigram which has sales in all 10 Canadian provinces.
  • Organigram submitted new product notifications to Health Canada for a vape pen portfolio and cannabis infused chocolates last month.
  • Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

Monday, November 11, 2019 - 9:10pm

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.

Key Points: 
  • Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.
  • Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
  • Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com .
  • Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD.

Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Monday, November 11, 2019 - 9:30pm

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, at 10:20 a.m. EST in New York, NY.

Key Points: 
  • Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, at 10:20 a.m. EST in New York, NY.
  • A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com.
  • A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
  • Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.

Castle Biosciences Reports Third Quarter 2019 Results

Monday, November 11, 2019 - 9:05pm

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the third quarter and nine months ended September 30, 2019.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the third quarter and nine months ended September 30, 2019.
  • Delivered 4,126 DecisionDx-Melanoma test reports in the 2019 third quarter, compared to 3,136 reports during the third quarter of 2018, representing growth of 32%.
  • Delivered 356 DecisionDx-UM test reports in the 2019 third quarter, compared to 324 reports during the third quarter of 2018, representing growth of 10%.
  • Castle Biosciences will hold a conference call on Monday, November 11, 2019, at 4:30 p.m. Eastern time to discuss its third quarter 2019 results and provide a corporate update.

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

Monday, November 11, 2019 - 8:00pm

The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019.

Key Points: 
  • The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019.
  • ERVEBO is currently under Priority Review with the U.S. Food and Drug Administration (FDA) with a target action date of March 14, 2020.
  • The European Commissions marketing authorization of ERVEBO is the result of an unprecedented collaboration for which the entire world should be proud.
  • After recognizing the need and urgency for an Ebola Zaire vaccine, many came together across sectors to answer the global call for outbreak preparedness.

Velmetia - 2019 Drug Insight Study with Sales Forecasting to 2021 - ResearchAndMarkets.com

Monday, November 11, 2019 - 7:21pm

The "Velmetia - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Velmetia - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Velmetia - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of the Velmetia covering the historical global sales and also provides the Velmetia sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Velmetia and emerging therapies in this space.

Epzicom - Drug Insight Report, 2019-2021 - ResearchAndMarkets.com

Monday, November 11, 2019 - 7:14pm

The "Epzicom - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epzicom - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Epzicom - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of the Epzicom covering the historical global sales and also provides the Epzicom sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Epzicom and emerging therapies in this space.